Scarica l'app Stockscreener
0.6451
0.21%
-0.0012
Standard Biotools Inc Borsa (LAB) Ultime notizie
Enterprise value to EBIT forward of Standard BioTools Inc. – BX:FLB - TradingView
Long Focus Capital Management, LLC Adds to Standard BioTools Inc - GuruFocus
Standard BioTools (LAB) Slides 4.99% to $0.71 as Selling Pressure PersistsFactor Valuation - Vinanet
Standard BioTools (LAB) holders report 7.3% stake in amended ownership filing - Stock Titan
Standard BioTools Inc.: Target Price Consensus and Analysts Recommendations | LAB | US34385P1084 - marketscreener.com
Standard BioTools (LAB): Long Focus Capital discloses 23.5M shares, 6% passive stake - Stock Titan
Standard BioTools (LAB) Short Interest & Short Float | Updated Aug 2026 $LAB - MarketBeat
Standard BioTools Inc (LAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Standard BioTools Inc (LAB) Stock News Today - TradingKey
Is Standard BioTools Inc (LAB) Overvalued After Q2 Loss? EPS: -$0.21, Revenue: $20.1M -- GF Score: 33/100 - GuruFocus
Standard BioTools Inc. (LAB) Stock Report: Evaluating a Potential 93% Upside in the Medical Devices Sector - DirectorsTalk Interviews
Standard BioTools (LAB) Holds Steady at $0.80: Consolidation or Pivot Point Ahead?Growth Stock Picks - dars.gov.et
BlackRock, Inc. Reduces Standard BioTools Inc (LAB) Stake -- Sha - GuruFocus
Standard BioTools Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Standard BioTools (NASDAQ:LAB) Issues Earnings Results - MarketBeat
Standard BioTools Q2 2026 Earnings: Cost Cuts Narrow the Adjusted EBITDA Loss - TradingKey
Standard BioTools Q2 revenue falls on consumables weakness - TradingView
STANDARD BIOTOOLS ($LAB) Releases Q2 2026 Earnings - Quiver Quantitative
STANDARD BIOTOOLS INC. Q2 2026: Revenue $20.1M, EPS $(0.07) — 10-Q Summary - TradingView
Standard BioTools: Q2 Earnings Snapshot - barchart.com
Standard BioTools (NASDAQ: LAB) Q2 revenue $20.1M as merger advances - Stock Titan
Standard BioTools Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Standard BioTools Reports Second Quarter 2026 Financial Results - The Manila Times
BRIEF-Standard BioTools Q2 EPS USD -0.07 - TradingView
Standard Biotools Inc. Withdraws Earnings Guidance for the Full Year 2026 - marketscreener.com
Price to sales forward of Standard BioTools Inc. – BX:FLB - TradingView
Standard BioTools (LAB) CEO has 362,625 shares withheld for taxes - stocktitan.net
Standard BioTools Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Standard BioTools Inc. expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Standard BioTools Inc. (NASDAQ:LAB) Short Interest Update - MarketBeat
BlackRock (LAB) reports 7.9M-share, 2.0% position in Standard BioTools - Stock Titan
Standard BioTools Updates Disclosure on Mass Cytometry Business Sale to Multiplex Bio Amid Strategic Portfolio Restructuring - Kalkine Media
Form 4 Standard Biotools Inc For: 28 July By Investing.com - Investing.com Nigeria
Standard BioTools sells mass cytometry unit, gets $30M buyout By Investing.com - Investing.com Nigeria
Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences - Moomoo
- SEC.gov
Standard BioTools (LAB) plans sale of Mass Cytometry business alongside Treeline deal - Stock Titan
Standard BioTools sells mass cytometry unit, gets $30M buyout - Investing.com
Standard BioTools Sells Mass Cytometry Business and Secures $30 Million Illumina Buyout Ahead of Treeline Merger - citybiz
Standard BioTools (NASDAQ: LAB) nets $30M Illumina buyout, sells mass cytometry arm - Stock Titan
Standard BiotoolsEnters Termination, Waiver And Release Agreement With Illumina On July 24, 2026SEC Filing - TradingView
Standard BioTools Sells Mass Cytometry Unit for $5 Million Note and Nets $30 Million From Illumina - TradingView
Standard BioTools Announces Sale of Mass Cytometry Business - GlobeNewswire
Standard BioTools Inc (LAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Standard BioTools Inc. Revenue Breakdown – NASDAQ:LAB - TradingView
Standard BioTools Ends Illumina Partnership, Sells Mass Cytometry Unit to Multiplex Bio for $5M - Kalkine Media
Form 4 Standard Biotools Inc For: 27 July By Investing.com - Investing.com Nigeria
Standard BioTools Inc. (LAB) CFO share withholding for tax obligations - Stock Titan
Standard BioTools Inc. Revenue Breakdown – GETTEX:FLB - TradingView
Standard BioTools Inc (LAB) Income Statement - TradingKey
LAB|Standard BioTools Inc|Price:0.833|Chg%:-0.042 - TradingKey
Standard BioTools Inc (LAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Standard BioTools Inc (LAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Standard BioTools Inc (LAB) Institutional Confidence - TradingKey
Standard BioTools Inc (LAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Standard BioTools Inc (LAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Standard BioTools Inc (LAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
LAB|Standard BioTools Inc|Price:0.802|Chg%:-0.031 - TradingKey
Standard BioTools Receives Nasdaq Bid Price Deficiency Notice - TipRanks
Standard BioTools Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Standard BioTools (NASDAQ: LAB) warned on Nasdaq minimum bid-price compliance - Stock Titan
LAB|Standard BioTools Inc|Price:0.801|Chg%:+0.001 - TradingKey
Standard BioTools Inc (LAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026 - Investing News Network
Standard BioTools will post its next update after market close Aug. 5 - Stock Titan
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):